Companies › Fusion Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FPI-2265 Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy) | PSMA, FOLH1 | Phase 2 | Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05219500 | FPI-2265 | Phase 2 | Metastatic Castration Resistant Prostate Cancer | Oncology | May 2025 |
| NCT06402331 | FPI-2265 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2026 |
| NCT06909825 | FPI-2265 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | May 2027 |
Clarity Pharmaceuticals Curium US ABX advanced biochemical compounds POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.